Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 38c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q3 EPS of ($0.35), $0.38 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $19.57 million versus the consensus estimate of $12.32 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Ross Stores (ROST) Tops Q2 EPS by 72c, Beats on Revenue
• Advance Auto Parts falls on revenue miss, weak guidance
• Splash Beverage Group Inc. (SBEV) files for 5M share offering by selling stockholders